New combo treatment aims to shrink tumors before lung cancer surgery
NCT ID NCT07354061
Summary
This study is testing if a targeted drug called ensartinib, taken as a daily pill, works well and is safe when combined with standard chemotherapy given before surgery. The goal is to shrink tumors in patients with a specific type of lung cancer (ALK-positive NSCLC) to make surgery more effective. Researchers will measure if the treatment completely eliminates cancer cells in the removed tumor and monitor patients' health for up to 10 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital
RECRUITINGXi’an, Shanxi, 710038, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.